In this edition of Market Checkup, health-care analysts David Williamson and Max Macaluso discuss today's biggest health-care news, including Amgen's multibillion-dollar acquisition of oncology specialist Onyx Pharmaceuticals, Rigel Pharmaceuticals' latest clinical trial disappointment, new allegations of a big pharma's misconduct in China, and a new opportunity in Eli Lilly's animal health division.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.